• Explore /
  • Poster
  • / Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of <sup>177</sup>Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).

Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Anis Hamid

Eastern Health and University of Melbourne, Melbourne, Australia

Anis Hamid , Michael S Hofman , Mathias Bressel , Louise Emmett , Anthony M. Joshua , Lavinia Anne Spain , Lisa Horvath , Megan Crumbaker , Anupama Pasam , Jason Callahan , Alisa Tubbs , Luisa Fernandez , Richard J. Wenstrup , Grace Kong , Jeremy Howard Lewin , Ben Tran , Arun Azad , Joseph D. Schonhoft , Rodney J. Hicks , Shahneen Sandhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5027)

DOI

10.1200/JCO.2022.40.16_suppl.5027

Abstract #

5027

Poster Bd #

211

Abstract Disclosures

Similar Posters

First Author: Anis Hamid

First Author: Justine Panian

First Author: Fadi Taza

First Author: Daniel Peter Petrylak